Drugs / PRP (Polyribosyl Ribitol Phosphate)
last change Feb 2004 re-read 2 minutes ago

PRP (Polyribosyl Ribitol Phosphate)

Developed for
haemophilus infectious disease
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00127855 Mar 2003 → Feb 2004 haemophilus infectious disease, meningococcal infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PRP (Polyribosyl Ribitol Phosphate) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00127855
Route Intramuscular “One dose was administered IM in deltoid region of left arm at Month 10 as booster” NCT00127855